BioSpace News Archive

Ocean Biomedical, Inc. announced that its joint venture partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, dosed its first patients in a Phase 1b clinical trial of its investigational VRON-0200 immunotherapy, which is being evaluated as a functional cure for patients with chronic Hepatitis B virus infection.

Virion Therapeutics, LLC and its Joint Venture partner, Ocean Biomedical, Inc., announced that the first patients have been dosed in the Phase 1b clinical trial of its investigational VRON-0200 immunotherapy, which is being evaluated as a functional cure for patients with chronic Hepatitis B virus infection.

Biosyngen’s TIL therapy BST02 for liver cancer was granted an approval for clinical trial by the US FDA.

Triveni Bio Inc. announced a $92 million series A financing co-led by Atlas Venture and Cormorant Asset Management, with participation from OrbiMed, the private equity business of Viking Global Investors, Invus, Polaris Partners, Alexandria Venture Investments, and other investors.

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company announced further alignment with the FDA Division of Anesthesiology, Addiction Medicine, and Pain Medicine in connection with the development of NRX-101 for treatment of Chronic Pain.

Tonix Pharmaceuticals Holding Corp. announced the completion of the clinical phase of the Phase 2 proof-of-concept, double-blind, randomized, placebo-controlled PREVENTION1 study of TNX-19002 as a potential treatment for the prevention of migraine headaches in chronic migraineurs.

Generation Bio Co. announced that it has reached two significant achievements through in vivo studies, including results generated as part of its collaboration with Moderna, Inc. First, Generation Bio has shown highly selective T cell targeting in vivo with its cell-targeted LNP platform in a humanized mouse model.

Alimera Sciences, Inc. today announced financial results for the third quarter of 2023. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.

HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for the third quarter and provided business updates.

Bausch + Lomb Corporation today announced three podium presentations and seven poster presentations during the American Academy of Ophthalmology (AAO) annual meeting, which will take place in San Francisco Nov. 3-6, 2023.